SILVER SPRING
Truxima interchangeability granted for rituximab
- Sponsor
- Celltrion
- Drug
- Truxima · rituximab
- Indication
- blood cancer
FDA grants interchangeability status to Celltrion's Truxima (rituximab), the first biosimilar to achieve this designation.
What this means
Truxima is a biosimilar version of the cancer drug rituximab, an antibody that targets a specific protein on certain immune cells. The FDA has now designated Truxima as interchangeable with its reference product, Rituxan. This means pharmacists in most states can automatically substitute Truxima for Rituxan without consulting the prescriber, potentially increasing access and lowering costs for patients with blood cancers.
Drug Watch — recent news on Truxima
- Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma - Business Wire
- Rituximab Anti-Drug Antibodies Emerge Early in FSGS but May Not Affect Efficacy - Renal and Urology News
- Rituximab Noninferior to Ocrelizumab for Newly Diagnosed Relapsing MS. - Optometry Advisor
- Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma - Business Wire
- Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma - news.bms.com
Sponsor Watch — recent news on Celltrion
- Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder
- What does the EU have that the U.S. does not?
- PepsiCo (PEP) Adds A New Director, Is The Discount To Fair Value Warranted?
- The S&P 500 Has Returned About 11% Annually Since 1958. Here's the ETF I'd Trust for the Next 30 Years.
- Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects?